Erschienen in:
01.12.2011 | Breast Oncology
Reply: Strategy for Nonresponder Breast Cancer Patients to Neoadjuvant Treatment
verfasst von:
Abigail S. Caudle, MD, Ana M. Gonzalez-Angulo, MD, Funda Meric-Bernstam, MD
Erschienen in:
Annals of Surgical Oncology
|
Sonderheft 3/2011
Einloggen, um Zugang zu erhalten
Excerpt
The letter from Dr. Batsis reflects the goal of tailoring cancer treatment regimens that maximize benefit while minimizing morbidity. This mission includes not only thoughtful selection of agents and therapeutic modalities but also defining the optimal order for their administration. While neoadjuvant chemotherapy (NCT) has similar survival outcomes as an adjuvant approach, there are clear benefits when used in the appropriate patients.
1 In addition to the fact that tumor downsizing increases breast conservation rates, it also decreases positive sentinel node rates, thus sparing women the morbidity of axillary node dissections, and allows for in vivo assessment of tumor response.
2 The use of NCT is reasonable in most patients who will require chemotherapy and can be closely monitored for response. …
